Stockreport

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

Natera, Inc.  (NTRA) 
Last natera, inc. earnings: 2/26 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.natera.com
PDF JAMA Oncology study highlights that Signatera-positive patients treated with celecoxib and conventional chemotherapy experienced a 40% reduction in risk of death, wherea [Read more]